Opdivo No Longer FDA-Approved for Small Cell Lung Cancer
In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.
In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.
Smoking is consistently seen as a risk for various cancers, and in recent years it has been connected to colorectal cancer in particular.
New mammogram-based risk measures based on brightness and texture improve breast cancer risk prediction beyond an established measure of mammographic density.
Higher proportions of patients in the low to middle income brackets were diagnosed with localized renal cell carcinoma in states allowing Medicaid expansion.
This study examined bladder cancer that developed after radiation for any cancer potentially affecting the organ, not just prostate cancer.
Use of computed tomography and bone scans in low-risk prostate cancer cases has been in decline, but doctors continue to order these imaging modalities despite professional guidelines that do not recommend such use.
Several previously FDA-approved medicines were approved for additional uses in November 2020.
Medicaid expansion under the Affordable Care Act was linked to an increase in early-stage cancer diagnoses in the first year after expansion.
The FDA has approved therapies for the treatment of COVID-19, leukemia, Ebola, and pediatric adrenocortical insufficiency in October 2020.
Interview study identifies men’s perception and concerns related to their prostate cancer journey.